These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 11489818)

  • 21. Expression of plasminogen activator inhibitors type 1 and type 3 and urokinase plasminogen activator protein and mRNA in breast cancer.
    Castelló R; Landete JM; España F; Vázquez C; Fuster C; Almenar SM; Ramón LA; Radtke KP; Estellés A
    Thromb Res; 2007; 120(5):753-62. PubMed ID: 17258797
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical value of components of the plasminogen activation system in ovarian cyst fluid.
    Boss EA; Massuger LF; Thomas CM; Geurts-Moespot A; van Schaik JH; Boonstra H; Sweep CG
    Anticancer Res; 2002; 22(1A):275-82. PubMed ID: 12017303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression of matrix metalloproteinases, their inhibitors, and urokinase plasminogen activator in human meningiomas.
    Siddique K; Yanamandra N; Gujrati M; Dinh D; Rao JS; Olivero W
    Int J Oncol; 2003 Feb; 22(2):289-94. PubMed ID: 12527924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion.
    Quemener C; Gabison EE; Naïmi B; Lescaille G; Bougatef F; Podgorniak MP; Labarchède G; Lebbé C; Calvo F; Menashi S; Mourah S
    Cancer Res; 2007 Jan; 67(1):9-15. PubMed ID: 17210677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasminogen fragmentation and increased production of extracellular matrix-degrading proteinases are associated with serous epithelial ovarian cancer progression.
    Murthi P; Barker G; Nowell CJ; Rice GE; Baker MS; Kalionis B; Quinn MA
    Gynecol Oncol; 2004 Jan; 92(1):80-8. PubMed ID: 14751142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
    Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
    Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
    J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
    Drew AF; Blick TJ; Lafleur MA; Tim EL; Robbie MJ; Rice GE; Quinn MA; Thompson EW
    Gynecol Oncol; 2004 Dec; 95(3):437-48. PubMed ID: 15581944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical involvement of ILK in TGFbeta1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.
    Lin SW; Ke FC; Hsiao PW; Lee PP; Lee MT; Hwang JJ
    Exp Cell Res; 2007 Feb; 313(3):602-13. PubMed ID: 17187779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer.
    Ho CH; Yuan CC; Liu SM
    Gynecol Oncol; 1999 Dec; 75(3):397-400. PubMed ID: 10600296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
    Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
    J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of the plasminogen activator inhibitor type-1 in epithelial ovarian cancer.
    Koensgen D; Mustea A; Denkert C; Sun PM; Lichtenegger W; Sehouli J
    Anticancer Res; 2006; 26(2C):1683-9. PubMed ID: 16617562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors.
    Huang LW; Garrett AP; Bell DA; Welch WR; Berkowitz RS; Mok SC
    Gynecol Oncol; 2000 Jun; 77(3):369-76. PubMed ID: 10831344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.
    Badier-Commander C; Verbeuren T; Lebard C; Michel JB; Jacob MP
    J Pathol; 2000 Sep; 192(1):105-12. PubMed ID: 10951407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression and localisation of extracellular matrix degrading proteases and their inhibitors during the oestrous cycle and after induced luteolysis in the bovine corpus luteum.
    Kliem H; Welter H; Kraetzl WD; Steffl M; Meyer HH; Schams D; Berisha B
    Reproduction; 2007 Sep; 134(3):535-47. PubMed ID: 17709571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
    Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
    Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary gelatinase activities (matrix metalloproteinases 2 and 9) in human bladder tumors.
    Di Carlo A; Terracciano D; Mariano A; Macchia V
    Oncol Rep; 2006 May; 15(5):1321-6. PubMed ID: 16596205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of MMP-1 and MMP-3 by cultured conjunctivochalasis fibroblasts.
    Li DQ; Meller D; Liu Y; Tseng SC
    Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):404-10. PubMed ID: 10670469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot AJ; van Tienoven DT; Beex LV; Sweep FC
    Thromb Haemost; 2004 Mar; 91(3):514-21. PubMed ID: 14983227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.